Skip to main content

Table 2 Multivariate survival analysis

From: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

  

Multivariate

Covariate

Baseline

Coefficient(bi)

HR(exp(bi)

95,0% CI for Exp(B)

p-value

Grade 2

Grade1

1,67

5,30

(0,52-53,75)

0,159

Grade 3

Grade1

3,45

31,65

(2,47-404,27)

0,008

ER

ER positive

2,59

13,39

(2,62-68,50)

0,002

TP53

TP53 wild type

1,75

5,73

(1,11-29,40)

0,036

Stage 3

Stage2

0,19

1,21

(0,20-7,03)

0,833

Stage 4

Stage2

2,00

7,38

(1,12-48,55)

0,038

ABCB1 _2

Methylated ABCB1 _2

-1,13

0,32

(0,05-2,20)

0,247

FOXC1 _3

Methylated FOXC1 _3

1,99

7,32

(1,11-48,31)

0,039

GSTP1 _2

Methylated GSTP1 _2

2,02

7,52

(1,76-32,07)

0,006

  1. Multivariate survival analysis using the Cox regression model using the categorical methylation data. Positive hazard ratios indicate an increased risk of dying from breast cancer and are calculated for the different covariates in reference to the baseline as given in the 2nd column.
Back to article page

Molecular Cancer

ISSN: 1476-4598